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Malignant neoplasms are consistently among the top four
leading causes of death in all age groups in the United
States, despite a concerted effort toward developing novel
therapeutic approaches [1]. Our understanding of and
therapeutic strategy for treating each of these neoplastic
diseases have been improved through decades of research
on the genetics, signaling pathways, and cellular biology
that govern tumor cell initiation, progression and mainte-
nance. Much of this work has concentrated on post-trans-
lational modifications and abnormalities at the DNA level,
including point mutations, amplifications/deletions, and
chromosomal translocations, and how these aberrant
events affect the expression and function of protein-
coding genes. Only recently has a novel class of conserved
gene regulatory molecules been identified as a major
contributor to malignant neoplastic disease. This review
focuses on how these small non-coding RNA molecules,
termed microRNAs (miRNAs), can function as oncogenes
or tumor suppressors, and how the misexpression of
miRNAs and dysregulation of factors that regulatemiRNAs
contribute to the tumorigenic process. Specific focus is
given to more recently discovered regulatory mechanisms
that go awry in cancer, andhow these changes altermiRNA
expression, processing, and function.
Introduction
MicroRNAs (miRNAs) are members of a larger class of non-
coding RNA that regulate a wide array of biological pro-
cesses [2], and concordantly have been found to be heavily
dysregulated in diseases, including cancer [3,4]. Importantly,
aberrant miRNA expression levels are linked to both facili-
tating and abrogating the tumorigenic process: they do so
through their ability to control the expression of thousands
of protein-coding and non-coding genes, and through
their ability to regulate transcription of genes via promoter-
associated RNAs (paRNAs) [5]. Currently there are 1,872
annotated human miRNA precursor genes that are pro-
cessed intow2,578 mature miRNA sequences (http://www.
mirbase.org), many of them with unknown functions. The
abundance of these small yet powerful RNAs and the
diversity of their function make miRNAs an exciting class of
understudied regulatory molecules. Further, as outlined
below, these molecules have the potential to be used as
biomarkers and therapeutic agents.
MiRNAs are transcribed from individual genes containing
their own promoters or intragenically from spliced portions
of protein-coding genes (some, called miRtrons, actually
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are almost exclusively transcribed by RNA polymerase II
and their primary transcripts (pri-miRNAs) are 50 capped
and 30 polyadenylated [7]. However, unlike their protein-
coding counterparts, miRNA function is driven by sequence
complementarity (Figure 1). The functional w20–22 nucleo-
tide (nt) sequence, referred to as the mature miRNA, is
sequentially processed from the pri-miRNA by the RNase
III family enzymes, DROSHA and DICER, with the first step
converting the pri-miRNA into the shorter pre-miRNA w85
nt stem-loop. The pre-miRNA product of DROSHA cleavage
is exported to the cytoplasm, where DICER processes it
to the w20–22 nt miRNA–miRNA* duplex (* indicates the
passenger strand, while the other complementary strand is
referred to as the mature or guide strand). The miRNA guide
strand associates with a protein complex termed the RNA-
induced silencing complex (RISC) and guides this complex
to target messenger RNAs (mRNAs) via base pairing be-
tween the miRNA and the cognate target mRNA sequence
[8]. In many cases base pairing occurs between nucleotides
2–8, the seed region of the miRNA; however, a recent unbi-
ased technique to identify miRNA–mRNA duplexes identified
four additional non-canonical binding clusters [9]. Collec-
tively, greater than 35% of the binding events were inde-
pendent of nucleotides 2–8, highlighting the complexity in
miRNA target identification. Regardless, once the miRNA is
bound to its target mRNA translation is inhibited through
one of two methods: mRNA degradation or destabiliza-
tion (thought to require full complementation between the
miRNA–mRNA duplex) or translational repression (mediated
by imperfect complementarity to the target mRNA) [10].
Since miRNA binding to mRNAs is often achieved with
imperfect complementarity, each miRNA can bind to and
regulate multiple protein-coding mRNAs and non-coding
RNAs. Therefore, aberrant expression of a single miRNA
can deleteriously affect the translation of multiple genes
within a cell, leading to profound phenotypic responses.
While unbeknownst to scientists for centuries, we now
appreciate that miRNA expression can classify disease
states, predict sensitivity to therapeutics, and can function
as therapeutic entities. This is best exemplified in the cancer
field, where misexpression of miRNAs alters numerous as-
pects of cellular function, such as differentiation, apoptosis,
and survival signaling, linking miRNAs to disease pathology.
In this review, we focus on the role of miRNAs as oncogenes
or tumor suppressors, how these regulatory entities can
themselves be regulated, and how the dysregulation of
miRNAs can promote pathological and morphological phe-
notypes such as therapeutic relapse. While it is impossible
to cover all of the advancements in the miRNA field, we will
attempt to highlight some recent findings that broaden
our conceptual notions with regard to miRNA function and
dysregulation in cancer.
MiRNA Biogenesis in Cancer
Over the past decade, numerous studies have shown that
miRNAs are misexpressed in tumors when compared with
normal tissue [11,12]. Additionally, some studies showed a
general downregulation of miRNAs in tumors. Rather than
highlighting individual miRNAs and their particular roles in
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Figure 1. Biogenesis of miRNAs.
In the canonical miRNA biogenesis pathway miRNAs are transcribed
by RNA polymerase II into long miRNA primary transcripts termed
pri-miRNAs. These pri-miRNAs serve as substrates for DROSHA and
DGCR8, with the former cleaving the flanking single-stranded RNA to
generate an w85 nt precursor miRNA (pre-miRNA). After nuclear
export to the cytoplasm via RanGTP–exportin-5, the majority of pre-
miRNAs are directly processed by DICER, found in a complex with
other dsRNA-binding proteins such as protein kinase RNA activator
(PACT) and transactivation response RNA binding protein (TRBP),
and are subsequently cleaved to generate a w22 nt miRNA duplex
(I). However, some pre-miRNAs are first cleaved by Ago2 to generate
an ac-pre-miRNA, which is then recognized by DICER (II). Once the
miRNA duplex is unwound and the passenger strand degraded, the
guide strand (highlighted in red), is incorporated into RISC, which con-
tains Ago and other proteins. A miRNA-loaded RISC mediates gene
silencing via mRNA target cleavage and degradation or translational
repression and deadenylation, depending on the complementarity be-
tween the miRNA and the targeted mRNA transcript. It should be
appreciated that there are additional non-canonical ways in which
miRNAs can be generated (i.e. miRtrons), and that miRNAs can func-
tion in non-classical ways.
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R763driving or antagonizing tumorigenic processes, we focus
here on the miRNA biogenesis machinery itself and how
various components of the machinery, post-transcriptional
miRNA changes, and alterations in RNA sequences are
dysregulated in cancer.
DROSHA and DICER
Roles for both DROSHA and DICER in the tumorigenic pro-
cess have been clearly defined through multiple reports
identifying their misexpression in human tumor tissue and
through detailed analysis of their function in genetically en-
gineered mouse models. A seminal study performed by
Merritt et al. [13] determined that high DICER and
DROSHA mRNA levels are associated with increased me-
dian survival (>11 years, vs. 2.66 years) in human ovarian
cancer. Furthermore, Karube et al. [14] found that reduced
DICER mRNA levels correlated with decreased post-opera-
tive survival in lung cancer patients. These findings are
complemented by animal studies where single-copy loss
of Dicer1 in a KrasLSL-G12D mutant lung cancer mouse
model was sufficient to reduce overall survival, while homo-
zygous deletion of Dicer1 did not result in an exaggeration
of this effect [15]. In fact, tumors that did develop in animals
that carried the homozygous deletion of Dicer still retained
a functional copy of Dicer; homozygous null tumors were
not identified. The study also found that DICER functions
as a haploinsufficient tumor suppressor in humans, given
that human tumors harbored lower levels of DICER but
were never found to be completely devoid of the protein.
Both in human samples with low DICER expression and in
the Dicer1+/- mice, a global reduction of miRNA levels
was observed as expected. This pro-tumorigenic effect
mediated by single-copy loss of DICER is perplexing, given
that homozygous mutations in tumor suppressor genes are
usually advantageous to tumor cells (Figure 2A). Others
have observed this phenomenon, however; for instance,
TAp63 directly transactivates the Dicer promoter, and in
TAp63-null mice metastatic tumors develop that harbor
aberrantly low but not absent Dicer levels [16]. This is an
important finding given that loss of p63 has been reported
to be associated with tumor metastasis [17]. Therefore, it is
likely that some amount of miRNA activity is required for
normal cellular growth and development and that complete
loss is lethal. Indeed, Dicer1-null mice die at E7.5 [18], while
Dicer1-hypomorphic mice are viable albeit with morpho-
logic abnormalities. Furthermore, injection of Dicer1-defi-
cient embryonic stem (ES) cells into nude mice failed to
generate tumors [19]. These studies suggest an essential
developmental role for DICER, which may or may not be
completely miRNA dependent [20]. Therefore, while loss
of DROSHA and DICER may not be an initiating event in
tumorigenesis, loss of miRNA expression as a result of
reduced biogenesis may allow for a more permissive
tumorigenic environment (Figure 2B).
Argonaute
Argonaute proteins, key components of RISC, induce endo-
nuclease cleavage of the mRNA and miRNA passenger
strand through intrinsic catalytic activity [8]. Similar to DICER
and DROSHA, dysregulation of Argonaute proteins also
occurs in cancer. For example, three of the four mammalian
Argonaute genes, AGO3 (EIF2C3), AGO1 (EIF2C1), and
AGO4 (EIF2C4), are frequently deleted in Wilms tumor of
the kidney and are associatedwith neuro-ectodermal tumors
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Figure 2. Consequences of aberrant miRNA biogenesis in cancer.
(A) Knudson’smodel of haploinsufficiency for a tumor suppressor gene (adapted fromFigure 1 of [144] with permission fromMacmillan Publishers
Ltdª 2000). The controlled expression of DICER has important functions in both developmental and tumorigenic processes. The red dashed line
indicates that a haploid dose of Dicer expression is sufficient for embryonic development, while haploidy is insufficient for tumor suppression.
Given that tumors retain some DICER expression and that Dicer loss (KO gene dosage) is embryonic lethal, the complete loss of Dicer is presum-
ably detrimental to both normal and tumor cell viability. As noted in the text, tumor suppressor genes such as Rb are haplosufficient for tumor
suppression (equivalent to the red dashed line), and usually require their complete loss to impair tumor-suppressive activity. (B) In general,
reduced miRNA levels are associated with tumor development, in part through decreased levels of miRNA biogenesis proteins such as DROSHA
and DICER. This suggests a majority of miRNAs harbor tumor-suppressive functions by controlling the expression of genes with oncogenic
activity when aberrantly expressed.Whether loss of DROSHA or DICER is an initiating event that allows for a permissive tumorigenic environment,
or whether established tumors actively suppress these proteins to maintain a tumorigenic state is still unclear. (C) Ago2 can function either as a
tumor suppressor (left panel) or as an oncogene (right panel) depending on cell context. As a tumor suppressor, loss of Ago2 would result in
reduced formation of Ago2–miRNP complexes and P-body formation, ultimately reducing miRNA activity. As a result, normal gene regulation
and dampening of transcriptional noise would decrease and potentially lead to enhanced abundance of aberrantly expressed transcripts that
harbor oncogenic activity. In some cancers, Ago2 expression is elevated, suggesting an oncogenic role. While the mechanism is unclear, it is
known that EGF–MAPK, AKT, and hypoxia signaling pathways promote the phosphorylation of Ago2 and its localization to P-bodies. Presumably
the resulting enhancement in miRNA activity reduces the level of certain tumor-suppressive transcripts that are highly abundant in those tumor
cells, or other Ago2-mediated mechanisms such as chromatin modification may be operating. Since proteasome inhibitors reduce Ago2 levels
[26], othermechanisms for gain of Ago2 expression in cancer could be through loss of certain E3 ubiquitin ligases, such asBRCA1, which is known
to be mutated or lost in certain breast cancers.
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R764[3,21,22]. In contrast to the generalized downregulation of
DROSHA and DICER in tumors, the expression of AGO
proteins is regulated in a cell-context-dependent manner
(Figure 2C). For instance, a recent study highlighted that in
melanoma cell lines AGO2 (EIF2C2) expression was lower
in both primary and metastatic melanoma samples com-
pared with normal epidermal melanocytes [23]. However,
observations from human breast and colon tumor samples
indicated that gain of AGO2 expression is associated with
a more aggressive phenotype and distant metastasis. Li
et al. [24] reported the gain of AGO2 protein expression in
colon cancer samples and in advanced tumors with distantmetastasis compared with adjacent normal tissue. In addi-
tion, Blenkiron et al. [25] found that breast tumors lacking
expression of estrogen receptor a (ERa) and the basal-like
subset of breast tumors, which are more aggressive and
metastatic compared with other breast cancer subtypes,
harbored significantly elevated AGO2 mRNA levels. Indeed,
the ectopic expression of AGO2 in ERa-positive MCF-7
breast cancer cells resulted in the loss of epithelial markers
such as E-cadherin, increased growth rates, and an en-
hanced ability to migrate in a wound healing assay, suggest-
ing a role for AGO2 in disease progression [26]. Furthermore,
AGO2 function is directly modulated by epidermal growth
Review
R765factor receptor (EGFR) signaling in ERa-negative breast
cancer under conditions of hypoxic stress. Here, EGFR can
directly bind and phosphorylate residue Y393 of AGO2 [27];
this phosphorylated form of AGO2 enhances cell survival
and invasiveness of breast cancer cells, and correlates
with poorer overall survival in breast cancer patients. How-
ever, it is unclear if this is a universal phosphorylation event
in all cancer types, given that other groups have found AGO2
to be phosphorylated on other residues such as Y529 [28],
and S387 via the kinase AKT3 [29]. The question also still re-
mains as to whether the alteration in AGO2 levels in cancer is
directly linked to gain or loss of miRNA activity. Unlike
DICER, AGO2 has been linked with other biochemical pro-
cesses, such as chromatin modification and facilitation
of spliceosome recruitment, DNA methylation, modulation
of RNA polymerase II elongation rate, and promoter-directed
transcriptional gene silencing [30,31].
LIN28
LIN28/LIN28B proteins are RNA-binding proteins that harbor
a cold-shock domain (CSD) and two Cys–Cys–His–Cys
(CCHC) zinc finger domains, providing the RNA-binding
function [32]. While normally only expressed at high levels
during development, these small proteins are unique in
their ability to convert human somatic cells to pluripotency
when co-expressed with the reprogramming factors OCT4,
NANOG and SOX2 [33]. Indeed, LIN28 is highly expressed
in ES cells as well as cancer stem cells in numerous cancer
types, including ovarian, breast, and non-small cell lung can-
cer (NSCLC) [34–36]. For this reason, LIN28 is viewed as an
oncogene, which can be targeted by the tumor-suppressive
miRNA let-7. Interestingly, it was discovered that a double
negative feedback loop existed whereby let-7 repressed
LIN28 through canonical targeting of the LIN28 30UTR,
and LIN28 itself could bind to a conserved terminal loop
of pri-let-7 and pre-let-7, preventing the processing of
mature let-7 miRNAs via DROSHA and DICER, respectively
(Figure 3A). An additional mechanism of let-7 repression by
LIN28 involves the terminal uridylation (addition of uridine
nucleotides) of the pre-let-7 through LIN28-mediated recruit-
ment of the terminal uridylyl transferase TUT4 complex. This
uridylation blocks DICER processing and leads to pre-let-7
degradation [36–38].
Adding to this complexity, there are signaling-mediated
regulatory circuits that control let-7 levels in a LIN28-depen-
dent fashion. Inflammatory signaling molecules such as
NF-kB and interleukin-6 (IL6) are pro-tumorigenic and can
promote cell growth, motility, and malignant transforma-
tion via activation of the transcription factor STAT3. This
signaling axis can also reduce the levels of the tumor-
suppressive let-7 by activating LIN28 transcription [39].
Furthermore, let-7 directly targets IL6 and LIN28, thereby
antagonizing let-7 transcriptional repression mediated by
inflammatory signaling, as well as subsequent STAT3 acti-
vation. A second LIN28-dependent mechanism involves the
oncogenic c-Myc transcription factor. Initially c-Myc was
reported to transcriptionally inhibit let-7 expression both
directly [40] and indirectly by modulating expression of
insulin-like growth factor II mRNA-binding protein 1 (IMP1)
[41]. However, c-Myc can also transactivate LIN28B, a
LIN28 homolog, resulting in repression of let-7 [42]. Given
that LIN28 may bind to RNA in a sequence-dependent rather
than structure-dependent manner, it remains unclear as to
whether other miRNAs are controlled by LIN28.More direct evidence supporting the oncogenic role of
LIN28 comes from studies in which forced expression of
Lin28 in NIH 3T3 murine fibroblasts resulted in colony for-
mation in soft agar and growth of small tumors in nude
mice [34]. Conversely, the loss of LIN28B in K562 leukemia
cells reduced tumor growth and promoted differentiation.
However, if LIN28 functions as a bona fide oncogene, then
Lin28a transgenic mice ought to harbor a greater propensity
for developing tumors compared with littermate controls.
The initial phenotype that emerged from these mice was
instead somewhat more complex. Lin28a transgenic mice
have larger body sizes, greater organ weights and bonemin-
eral density, and also show a delay in the onset of puberty
[43]. Some of these phenotypes support the hypothesis
that Lin28 promotes expansion of transit-amplifying or
tissue stem cells. Additionally, Lin28a transgenic mice have
increased glucose utilization, whichmay provide an explana-
tion for the heightened energy demands these mice would
require for this overgrowth phenotype. Yet these mice did
not appear to develop outright tumors, even though stem-
cell expansion and aerobic glycolysis are processes crucial
for tumorigenesis.
Despite these initial findings, it appears that LIN28 may
function as an oncogene in a cell-context-dependent
manner. Mice harboring an inducible form of Lin28a (iLin28a)
have enhanced tissue regenerative capacity — specifically,
epidermal would healing and hair regrowth, as well as faster
digit repair rates [44]. Importantly, in these iLin28 mice, the
bioenergetic state is altered during tissue repair such that
these cells undergo greater mitochondria-mediated oxida-
tive phosphorylation. This is contrary to the suggestion
that LIN28 promotes aerobic glycolysis, a tumorigenic pro-
cess, and supports the notion that LIN28 is important for
normal physiological bioenergetic processes. However,
expression of Lin28b specifically in the intermediate meso-
derm of themouse kidney led to robust development of renal
tumor formation similar in morphology to human Wilms tu-
mors [45]. Interestingly, expression of Lin28b in other kidney
lineages did not recapitulate this phenotype, suggesting that
aberrant expression of LIN28B in early renal progenitor cells
may result in Wilms tumor formation. Given these recent
findings, it would be interesting to determine whether pro-
genitor cells in other tissues with aberrant LIN28 expression
can also promote tumor formation, and whether this process
requires the expected inactivation of let-7.
Regulation of Other miRNA Biogenesis Pathway Factors
in Cancer
Like most proteins, DROSHA and DICER work collectively
with other factors to achieve a cellular response; therefore,
dysregulation of these additional factors can also alter
DROSHA and DICER activity and contribute to neoplastic
disease. For example, studies have highlighted the essential
role of the p68 and p72 DEAD-box RNA helicases in regu-
latingmiRNAprocessing during the pri-miRNA to pre-miRNA
processing stage via DROSHA (Figure 3B). In mice, RNA–
chromatin immunoprecipitation assays identified that p68
and p72 are within the Drosha complex, and that loss of
p68 and p72 results in embryonic lethality, similar to the
phenotype observed in the Dicer knockout mice [46]. More
specifically, ERa was shown to associate with p72 when
17b-estradiol was present. This association prevented
DROSHA from interacting with p72 and processing the pri-
miRNA, essentially through competitive inhibition [47,48].
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Figure 3. Mechanisms disrupting or promot-
ing miRNA biogenesis in cancer.
(A) Lin28-mediated regulation of let-7. The left
panel depicts Lin28 binding to the stem-loop
region of either pri-let-7 or pre-let-7, prevent-
ing components of the miRNA biogenesis
machinery from recognizing their respective
substrates, and ultimately reducing mature
let-7 levels. The right panel depicts a separate
but not mutually exclusive mechanism,
whereby Lin28 recruits TUT4 to the pre-let-7
substrate resulting in polyuridylation and
degradation. It is unclear if other miRNAs are
controlled by Lin28. (B) Depiction of how
DEAD-box RNA helicases can control miRNA
biogenesis. Specifically, p72 and p68 aid in
DROSHA-mediated processing of pri-miRNA
transcripts and, when these biogenesis fac-
tors recruit other proteins, such as ERa or
SMADs, processing activity can be inhibited
or promoted, respectively. Other proteins,
such as KSRP and NF45/NF90, represent
other classes of biogenesis factors but func-
tion in a similar manner to alter biogenesis
activity.
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R766This is a crucial finding given that, in breast cancer, estrogen
status is one of the most informative clinical diagnostic tools
and dictates treatment regimens for breast cancer patients.
Furthermore, these data suggest that in ERa-positive breast
tumors, there may be a global reduction of a subset of
miRNAs that may be present in other breast tumor subtypes.
A similar, but activating, function is observed when R-
SMADs, receptor-regulated transcription factors that func-
tion in response to transforming growth factor b (TGFb)
signaling, associate with p68 and DROSHA to enhance
miRNA processing (Figure 3B) [49,50]. Since the activity of
DROSHA is contained in the nuclear compartment, shuttling
of R-SMADs into the nucleus can enhance DROSHA-medi-
ated processing of some pri-miRNAs in a sequence-specific
manner. Indeed, following TGFb signaling — a fundamental
pathway heavily dysregulated in cancer — R-SMADs enter
the nucleus and cooperate with DROSHA to enhance the
processing of the oncogenic miRNA, miR-21 [51]. The result,
at least in vascular smooth muscle cells, is that R-SMADsignaling stimulates the biogenesis
of miR-21, subsequently repressing
expression of the tumor suppressor
programmed cell death 4 (PDCD4).
This process occurs in other systems
as well and involves binding of R-
SMADs to a conserved RNA sequence
in other miRNAs, such as miR-105,
miR-199a, and miR-421, to induce their
processing [52].
The KH-type splicing regulator pro-
tein (KSRP) has been implicated in
regulating both DROSHA and DICER
processingofmiRNAs [53]. Specifically,
KSRPcanassociatewithbothDROSHA
andDICERcomplexes, andknockdown
of KSRP in HeLa cervical carcinoma
cells led to a reduction of mature
miRNAs, including let-7. While the
mechanism of action is still unclear, itis thought that KSRP aids in the enzymatic cropping activity
of DROSHA and DICER on the respective pri/pre-miRNA
substrates. Conversely, nuclear factors NF45 and NF90 can
reduce pre-let-7 levels by directly binding the pre-miRNA
stem loop, in turn preventing DROSHA binding [54].
RNA-binding proteins (RBPs) can directly bind to miRNA
biogenesis proteins to promote or inhibit miRNA activity
within a cell. Specifically, the RBP AUF1 can recognize
DICER mRNA, in turn decreasing the production of the
DICER protein [55,56]. As expected, this results in a global
loss of mature miRNAs and, importantly, in tumor samples
DICER levels were found to be low and AUF1 levels high.
HuR, another RBP, can alter AGO2 activity by facilitating tar-
geting of the miRNA-loaded RISC complex to its respective
mRNA targets [57,58]. It is still unclear whether this occurs
through a direct interaction between HuR and AGO2 or
whether HuR stabilizes transcripts and, due to higher tran-
script abundance, indirectly results in a greater targeting fre-
quency by RISC. Regardless, it is interesting that, at almost
Review
R767every level of miRNA biogenesis, there are regulatory pro-
cesses present to keep miRNA abundance and activity in
check and that, when these proteins are dysregulated in can-
cer, aberrant miRNA expression patterns are observed.
Finally, and perhaps not surprisingly, miRNAs themselves
are negative regulators of DICER. The miRNA family miR-
103/107 can attenuate miRNA biogenesis through reducing
endogenous levels of DICER [59]. High levels of miR-103/
107 have been observed in breast cancer specimens and
are associated with metastatic disease and poor clinical
outcome, contributing to an epithelial-to-mesenchymal
phenotype.
Regulating the Regulators — How Many Ways?
Over the past decade it has become clear that miRNAs can
serve asmaster regulators that target numerous geneswithin
a single pathway, or multiple genes within a variety of path-
ways that feed into a single cellular phenotype. Initially,
what was less well understood was how these master regu-
lators are themselves controlled beyond the standardmiRNA
biogenesis pathways discussed above. Recent studies have
begun to shed light on this issue and have opened a new
realm of possibilities for how small RNAs can act in concert
with proteins to regulate complex cellular processes.
Transcriptional Activation and Repression
While some miRNAs are transcribed by RNA polymerase
III [60], a majority of miRNAs are transcribed by RNA poly-
merase II [61] and are subjected to the same regulatory pro-
cesses as mRNA transcripts. Large-scale mapping studies
identified high frequencies of CpG islands, TATA boxes
and TFIIB recognition sites, and the presence of histone
modifications within miRNA promoters (Figure 4A) [61,62].
Furthermore, many key transcription factors, including
known oncogenes and tumor suppressors, regulate the
expression of primary miRNA transcripts. For example, c-
Myc binding to E-box elements in the promoter of the mir-
17w92 gene induces transcriptional activation of mir-
17w92 [63]. In addition, c-Myc can also promote the tran-
scription of E2F1 [64], which in turn is repressed by miR-
17w92, generating a feedback loop whereby E2F1 levels
can be easily regulated. Given that E2F1 is a crucial cell-cy-
cle regulator, the ability to tightly regulate its expression is
critical for maintaining cellular homeostasis. In other cases,
and in line with its oncogenic role, c-Myc imposes negative
transcriptional activity on certain tumor-suppressive miR-
NAs such as mir-15a, mir-34, and let-7 families [40].
ThemiR-34–p53 regulatory axis is another example of how
transcriptional regulation of a miRNA can result in fine tuning
of gene expression levels (Figure 4B), in this case through a
feed-forward system to mediate tumor-suppressive pheno-
types [65,66]. The miR-34 family of miRNAs, including miR-
34a/b/c, promotes cell-cycle arrest, cell senescence, and
apoptosis in cancer, similar to the phenotypes mediated by
p53 [67]. In p53 knockout mice, whole body irradiation failed
to induce miR-34a expression, an observation noted to
occur in wild-type mice, which suggests that miR-34a levels
depend upon p53. Indeed, p53 can directly bind the pro-
moter ofmir-34a andmir-34b/c and induce their expression,
and miR-34a can indirectly induce p53 by targeting the
deacetylase SIRT1, which negatively regulates p53. Other
regulatory proteins that affect the expression of miR-34a in
cancer include NF-kB, which can transcriptionally enhance
miR-34a levels [68], and CCAAT enhancer binding protein a(CEBPa), which when mutated results in lower miR-34a
levels and enhanced expression of miR-34a targets, such
as E2F3, in turn resulting in acute myeloid leukemia [69].
miR-21 is highly expressed in a variety of cancers,
including breast, ovarian, colorectal, lung, and leukemia
[70], and targets tumor suppressors such as phosphatase
and tensin homolog (PTEN) [71] and tropomyosin 1 (TPM1)
[72]. Much is known about the transcriptional control of
miR-21. Despite being located in an intron of the TMEM49
gene, approximately seven different transcription factor
binding sites are present within a w500 base pair region
upstream of mir-21, some of which are recognized by tran-
scription factors that are mutated or dysregulated in cancer,
such as p53, CEBPa, and STAT3 [70,73]. These sites are
functional, since cells treated with agents that stimulate or
inhibit the activity of these transcription factors promote
stimulation or repression of pri-miR-21 levels, respectively.
Additionally, some of these transcription factors are mem-
bers of a regulatory feedback network controlled by miR-
21. For instance, arsenite can transform human embryonic
lung fibroblast cells via activation of the mitogen-activated
protein kinases (MAPKs) ERK and JNK, promoting NF-kB
and c-Jun-mediated transcriptional activation of miR-21
[74]. Furthermore, miR-21 subsequently inhibits PDCD4
and the Sprouty gene SPRY1, which negatively regulates
ERK/JNK signaling, therebymaintaining a transformed state.
Other examples of negative feedback loopswith transcrip-
tional regulation of miRNAs at the hub of these interactions
includemir-200 and the transcriptional repressors zinc finger
E-box binding homeobox 1 (ZEB1) and SMAD interacting
protein 1 (SIP1) [75],mir-124 and the kruppel-type zinc finger
transcriptional repressor RE-1-silencing transcription factor
(REST) [76], mir-206 through the c-fos serum response
element-binding transcription factor (SRF) [77] and the nu-
clear steroid hormone receptor ERa [78], and the mir-106b
cluster by the transcriptional activator E2F [79]. Finally, these
transcriptional regulatory networks can be modulated by
outside signals, such as platelet-derived growth factor
(PDGF) and TGFb [80], suggesting miRNA activity is kept in
check inside the cell and that miRNAs can promote switches
in cellular gene expression patterns upon growth factor and
cytokine stimulation.
Promoter Methylation of miRNA Genes
The field of epigenetics has expanded greatly in the past
decade, and with it the discovery that miRNA genes can be
epigenetically silenced through DNA methylation. The first
evidence for miRNA silencing via methylation came from
microarray studies on T24 bladder cancer cells treated with
or without 5-aza-20-deoxycytidine (5-aza-dC), a DNAmethyl-
transferase inhibitor [81]. One of the miRNAs shown to be
strongly upregulated after treatment-induced DNA demethy-
lationwasmiR-127. ThismiRNAwas also shown to be down-
regulated in primary prostate, bladder, and colon cancer
samples compared with matched normal tissues. Further
experimental evidence indicates miR-127 functions as a
tumor suppressor by targeting the proto-oncogene BCL6.
Other studies supporting epigenetic silencing of miRNAs
found mir-124 and mir-34b/c to be hypermethylated
in colorectal cancer cells through dysregulation of the
DNA methyltransferase genes (DMNT1 and DNMT3B) [82].
Furthermore, 5-aza-dC can restore endogenous miR-34
expression in colorectal cancer cells harboring a hyperme-
thylated mir-34 promoter [83].
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Figure 4. Factors regulating miRNA abundance.
(A) Transcriptional regulation of miRNAs. Similar to other RNA polymerase II transcripts, miRNA genes harbor TATA boxes and TFIIB recognition
sites upstream of the transcription start site (TSS; arrow). MiRNA genes contain upstream enhancer/repressor elements, and promoter regions,
indicating that miRNAs are subjected to CpG promoter methylation (yellow CpG box) via DNA methyltransferase (DMNT), histone modification
(blue circles), as well as other regulatory events. Transcription factors (TFs) such as p53, Myc, and REST can bind to canonical sites within miRNA
promoters to either promote or repress transcriptional activation. These TFs, and therefore the miRNA genes, can bemisexpressed if the chemo-
kine, hormone, or growth factor signaling pathways that control these TFs become dysregulated. Importantly, while the TSSs of miRNA genes are
sometimesw5–10 kb away from the pre-miRNA sequence (yellow box) [61], the promoter regions can be up to 50 kb away, making it difficult to
study transcriptional regulation of particular miRNAs. (B) Examples of transcriptional networks that control miRNA expression patterns [145]. Uni-
lateral negative feedback loops occur when certain TFs promote miRNAs that are responsible for dampening the activity of the same TFs. Recip-
rocal and/or double negative feedback loops occur when certain TFs repressmiRNAs that promote the negative regulation of the same TFs [146].
These networks result in either the oscillatory or stable expression of both the TF and themiRNA. This is in contrast to TFs involved in feed-forward
loops, which regulate miRNAs in a manner that reinforces the initial signaling activity (i.e. NF-kB enhancement of IL-6 through repression of let-7
levels). (C) Factors that control miRNA stability and decay. XRN2 represents a class of 5’/3’ exonucleases that can reducemiRNA levels andwas
initially identified in C. elegans. However, in an immortalized human lung epithelial cell model, serum-mediated differentiation of these cells is
blocked by forced XRN2 expression. SND1, a member of the 3’/5’ exonucleases, has similar activity on miRNAs in A. thaliana. The overexpres-
sion of SND1 enhances colon cancer proliferation and anchorage-independent growth by controlling APC expression.While gain of exonucleases
occurs during tumorigenesis, in part to reduce miRNA levels, the loss of miRNA-stabilizing proteins such as GLD2 has also been noted to occur.
Here, GLD2 promotes polyadenylation of miRNAs and therefore protects miRNAs from exonuclease activity.
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silencing various tumor suppressor miRNAs in the cell
(Figure 4A). For example, in NSCLC, mir-34b/c methylation
and accompanying low levels of maturemiR-34b/c are asso-
ciated with higher rates of recurrence and decreased overall
survival [84]. In breast cancer,mir-34b/cmethylation results
in the enhanced self-renewal capacity of breast cancer
tumor-initiating cells [85], presumably due to loss of miR-
34b/c levels, given that ectopic miR-34c expression abro-
gated these processes. Other miRNA genes known to be
methylated in solid cancers are mir-34a [86], mir-145, mir-
200, mir-9, and mir-193a [82]. As epigenetic cancer thera-
peutics are emerging as a new class of anti-tumorigenic
agents, it will be important to consider how these agents
affect miRNA gene expression, and whether these effects
might help to generate therapeutic efficacy through restora-
tion of miRNA expression.
While certain tumor-suppressive miRNAs harbor hyper-
methylated CpG islands in their promoter, other reports
have also identified promoter hypomethylation of miRNAs.
Although the let-7 family is largely considered to be a
tumor-suppressive group of miRNAs, let-7a-3 displays
oncogenic activity in lung cancer by supporting anchorage-
independent growth and the upregulation of oncogenic
genes, such as CDK6, CXCL5, and PCNA [87]. In support
of an oncogenic role for let-7a-3, its promoter was hypome-
thylated in lung cancer samples compared with normal tis-
sue. miR-200a/b is another tumor-suppressive miRNA that
in pancreatic cancer possesses oncogenic activity. Here,
the levels of miR-200b are elevated in the serum of patient
samples, and in pancreatic cancer cells the mir-200a/b
promoter is hypomethylated [88]. Therefore, both DNA
hypermethylation and hypomethylation will serve as useful
biomarkers for detecting cancer and predicting patient
outcomes.
miRNA Stability and Decay
While miRNAs can be regulated at any stage during the
biogenesis pathway, the regulatory processes governing
the decay rates and the resulting half-lives of miRNAs are
less well understood (Figure 4C). In Caenorhabditis elegans,
degradation of miRNAs is mediated by the 50/30 exoribo-
nuclease XRN2 [89], and in plants SND1 is a 30/50 exonu-
clease that degrades single-stranded RNA in a sequence-
dependent manner [90]. Other proteins, such as the methyl-
transferase HEN1, can methylate the last ribose molecule
on miRNAs, resulting in the protection of miRNA from
degradation by exonucleases such as SND1 [91]. Impor-
tantly, these proteins are highly conserved in mammalian
cells, and some appear to be aberrantly expressed in
several cancer subtypes. A genome-wide association study
on spontaneous lung tumor incidence in inbred mice iden-
tified that a single nucleotide polymorphism (SNP),
rs27328255, was strongly associated in cis with Xrn2 tran-
script levels [92]. Additionally, forced expression of XRN2
inhibits differentiation and promotes proliferation of immor-
talized human lung epithelial cells. In another study, SND1
was found to be elevated over fivefold in colon cancer sam-
ples compared with normal tissue, and overexpression of
SND1 enhanced colon cancer proliferation and
anchorage-independent growth by controlling expression
of the adenomatous polyposis coli (APC) tumor suppressor
[93]. While it has been shown that RRP41 and XRN1 exonu-
cleases can destabilize miR-382 in HEK293 humanembryonic kidney cells [94], there has been no direct evi-
dence as yet that links the degradation of miRNAs via exo-
nucleases to tumorigenic processes.
Similar to mRNA, miRNAs can be monoadenylated or
polyadenylated on their 30 end, resulting in stabilization of
the miRNA. Monoadenylation of miRNA is mediated by
the cytoplasmic poly(A) polymerase GLD2 [95,96], which
confers protection from exonuclease activity in cancer
cell lines. Furthermore, the process of monoadenylation
is in direct competition with oligo-uridylation. An example
of this involves the TUT4–let-7 axis [97], where the TUT4-
uridylated let-7 miRNA fails to be recognized by DICER
and undergoes degradation. In contrast to the ribonucle-
ases mentioned above, meta-analysis indicates that these
RNA-modifying enzymes, such as GLD2, are downregu-
lated in several cancers, including a variety of lung and
digestive carcinomas as well as invasive breast cancer
[98,99]. Although not all cancers have lost GLD2, it would
be interesting to determine whether the reduced stability
of tumor-suppressive miRNAs is playing a biological role
in promoting tumorigenesis in cancers that do lack GLD2.
Finally, there are some sequence-motif-dependent pro-
cesses that mediate miRNA decay, such as those involving
AU-rich elements (AREs) within the mature miRNA se-
quence. Hwang et al. [100] identified a hexanucleotide
element that directs miRNA nuclear import and also
affected miRNA stability, although the exact mechanism
is still unclear.
RNA-Binding Factors Controlling miRNA Levels and
Activity
The concept of an RBP regulating miRNA levels should not
be surprising, given that miRNA biogenesis requires RNase
III enzymes to sequentially process a pri-miRNA to a mature
miRNA. The discovery of the let-7–LIN28 axis, however, has
opened up the possibility that other classes of RBPs could
interact with the secondary structure conferred by a miRNA
transcript or with a specific sequence in the miRNA to regu-
late the stability and function of these miRNAs (Figure 5A).
PUMILIO, an RBP not involved in miRNA biogenesis
but rather in promoting miRNA activity [101], can induce
conformational changes in the target mRNA, allowing for
greater accessibility of RISC. Specifically, Kedde et al.
[102] demonstrated in MCF-7 breast cancer cell lines that a
PUMILIO-induced conformational change in the 30UTR of
the cyclin-dependent kinase inhibitor p27Kip1 transcript
gave miR-221/222 better access to the cognate target site
within the p27 Kip1 mRNA. The involvement of PUMILIO has
been observed in other cancers, such as bladder cancer,
where miR-502 and miR-125b target E2F3 in the presence
of PUMILIO [103]. Interestingly, Murata et al. [104] used a
screening method to find PUMILIO regulatory elements
(PREs; UGUAXAUA) within 30UTRs and found that 30UTRs
harboring putative PREs were lost due to proximal polyade-
nylation usage. Presumably if PREs exist in other 30UTRs,
PUMILIO could be a global regulator of miRNA activity.
This is also important given that our current methodology
for finding miRNA target sites is based on target prediction
software and does not take into account target-site accessi-
bility with competing RBPs, such as LIN28 or PUMILIO.
RBM38 is an RBP that inhibits miRNA function under
stress conditions in breast cancer. RBM38 is upregulated
in a p53-dependent manner after induction of DNA damage
and binds to U-rich regions in the 30UTRs of numerous p53
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cell states, such as quiescence, presumably due to complex or secondary structures in the mRNA preventing miRNA–RISC binding. After growth
factor stimulation, transcripts that harbor PUMILIO response elements (PREs) will bind to PUMILIO, resulting in a change in the secondary struc-
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R771target genes, in turn protecting them from miRNA-mediated
AGO2-dependent degradation [105]. This indicates that
RBM38 is a crucial mediator of p53 function. Interestingly,
the promoter of RBM38 is methylated in many p53 wild-
type tumors [106], suggesting that some tumors abrogate
p53 signaling not by mutation of p53, but through miRNA-
mediated targeting of crucial p53 effectors. This form of
competition for miRNA-binding sites by RBPs can be found
in other tumor systems as well. In the leukemic setting,
miR-328 serves as a decoy by interfering with binding
of the translational regulator protein hnRNP E2 to the
master myeloid differentiation regulator CEBPa. Canoni-
cally, miR-328 serves as a tumor suppressor by targeting
proto-oncogene serine/threonine-protein kinase PIM1;
however, another tumor-suppressive action of miR-328 is
through the recognition of miR-328 by hnRNP E2 [107].
This interaction prevents hnRNP E2 from translationally
repressing CEBPa, meaning that, when cellular levels of
miR-328 are high, miR-328 binds hnRNP E2, in turn protect-
ing CEPBa and promoting the differentiation of leukemic
blast cells.
HuR is another RBP that cooperates and competes with
miRNA activity [106]. HuR is a ubiquitously expressed mem-
ber of the ELAV family of RBPs and can predominantly
stabilize mRNA transcripts by binding AREs. HuR is mainly
restricted to the nucleus; however, under conditions of cell
stress, HuR translocates to the cytoplasm to promote
stabilization of mRNA transcripts [108,109]. MiRNAs were
first shown to be affected by HuR when cationic amino
acid transporter 1 (CAT-1) translation was repressed by
miR-122, specifically in the context of HuR binding to an
ARE in the CAT-1 30UTR [110]. A presumed mechanism for
this observation, at least under states of cell stress, is that
HuR could promote CAT-1 mRNA release from P-bodies,
where miR-122 would normally be mediating repressive
activity on the transcript. In subsequent studies, miR-331
and miR-16 were found to control cyclooxygenase-2 (COX-
2) and v-erb-b2 avian erythroblastic leukemia viral oncogene
homolog 2 (ERBB-2) transcript levels via competition with
HuR binding [111,112]. In addition, HuR promotes miRNA
activity because let-7-mediated targeting and repression of
the c-Myc oncogene required the presence of HuR [113].
This positive regulatory loop mediated by HuR binding was
also observed with miR-19-mediated repression of the
RhoB mRNA [114]. Finally, HuR can also be modulated by
miRNAs in cancer. For example, miR-519, a tumor-suppres-
sive miRNA, promotes anti-proliferative properties in cervi-
cal, colon, and ovarian cancer lines through targeting
and reducing HuR transcripts [115]. Furthermore, miR-519
and HuR levels are inversely correlated in many cancer
samples — specifically, miR-519 levels are low and HuR
levels are elevated [116]. As more RBPs are found to control
miRNA activity, it will be important to improve the categori-
zation of their respective activity in an effort to identify
universal mechanisms of action that can be exploited for
therapeutic potential.
miRNA Editing
Adenosine deaminases (ADARs) are a family of enzymes
that mediate adenosine to inosine editing of RNA molecules.
This process results in RNA and protein diversity in higher
eukaryotes by altering codons in the mRNA [117,118]. These
enzymes classically recognize double-stranded RNA struc-
tures within an mRNA transcript while still in the nucleus;however, certain edited forms of miRNAs have also been
identified. Specifically, cDNAs obtained from multiple tis-
sues, including brain, indicate that pri-miR-22 is heavily
edited [119]. Furthermore, ectopic expression of ADAR1 pro-
moted the editing of these same residues on the pri-miR-22.
Editing of pri-miRNAswould havemajor consequences for
miRNA biogenesis and function (Figure 5B). First, DICER
activity on the pre-miRNA substrate heavily depends on
proper base pairing within the stem region. If adenosines
were edited to inosines near the region where DICER
cleaves, then further processing of the miRNA would be
compromised. Consistent with this notion, an artificially
edited pri-miR-142 expressed in HEK293 cells could not be
processed, resulting in accumulation of the pri-miRNA tran-
script and degradation of mature miR-142 via Tudor-SN, an
inosine-specific ribonuclease [120].
More importantly, editing within the 20–22 nt portion of the
mature miRNA would alter the target mRNA repertoire for
that particular miRNA. For example, adenosines, which nor-
mally base pair with uridine, if edited to inosine would func-
tion as guanine and base pair with cytidine. A study by
Choudhury et al. [121] exemplifies this point, finding that
miR-376a* editing was significantly reduced in high-grade
human glioma samples. In this model, U87 glioma cells sta-
bly expressing an unedited miR-376a* (miR-376a*A) were
highly metastatic, while cells expressing the edited form
(miR-376*G) were not as invasive. Furthermore, miR-376a*
A targeted RAP2A, a gene that encodes a protein involved
in both the regulation of dendrite and axonal branching as
well as cancer cell migration, whereas miR-376a*G targeted
autocrine motility factor (AMFR), a newly identified player in
glioma. The restoration of these two genes in each respec-
tive model can rescue the phenotypes observed, suggesting
that differential targeting of the unedited/edited forms of
miR-376a*, rather than just the gain or loss of the targets
themselves, drive these phenotypes.
There are other examples of RNA editing in cancer (see re-
view by Skarda et al. [122]), as well as databases compiling
particular miRNA sequences that are subject to RNA editing
[123]. Overall, it is clear that RNA editing is modified in tu-
mors on a global scale; however, more work is required to
understand the role of miRNA editing in the processes
of tumorigenesis. Eventually, this knowledge could be ex-
ploited for diagnostic, prognostic, and therapeutic value.
The Competing Endogenous RNA Network
Competing endogenous RNAs (ceRNAs) regulate miRNA
activity on a particular target mRNA by competing with other
RNA transcripts for miRNA binding, and furthermore co-
regulate each other in a complex ceRNA network (Figure 6)
[124]. Recent examples of this network highlight the role
of transcribed pseudogenes — evolutionary remnants of
ancestral genes that do not code for protein, yet contain
target sites for miRNAs and therefore serve as miRNA
‘sponges’, allowing for known miRNA-regulated protein-
coding transcripts to escape miRNA regulation. The PTEN–
PTENP1 regulatory axis was the first ceRNA network shown
to exist in human cancer [125]. PTENP1 is a pseudogene
highly homologous to the tumor suppressor PTEN. Since
the 30UTR of PTENP1 is highly conserved with that of
PTEN, especially within the miRNA-binding sites, miRNAs
that bind to PTEN could be sequestered away by PTENP1.
In this way PTENP1 functions as an endogenous competitor
allowing for enhanced translation of PTEN. Indeed, miR-17,
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In the ceRNA network, ceRNAs can affect miRNA targeting primarily by acting as sponges. Left: given that many genes also have a number of
pseudogenes with conserved miRNA-binding sites, as is the case with PTEN, the abundance of the pseudogene (here, PTENP1) will influence
the strength of the regulatory action of a particular miRNA on the intended mRNA target (in this case, PTEN). However, the system is oscillatory
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the miR-372-mediated regulation of PRKACB.
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and importantly PTENP1 can also function as a tumor sup-
pressor. Lastly, the expression ofPTENP1 results in elevated
PTEN levels and inhibition of growth in prostate cancer lines.
Since this discovery, other ceRNA networks have been
found in prostate cancer, glioblastoma, and melanoma.
There have been PTEN ceRNA networks that include genes
such as VAPA and ZEB [126,127], and others such as
KRAS-KRAS1P, CD44-CDC42, and HULC-CREB [128] (see
references for more detailed information). The long non-
coding RNA HULC serves as a ceRNA by inhibiting miR-
372 activity and functions as a sponge allowing for the
de-repression of protein kinase cAMP-dependent catalytic
b (PRKACB). This kinase can then phosphorylate cAMP
response element binding protein (CREB) and in turn pro-
mote the expression of HULC in an auto-regulatory fashion.
Recent work also indicates that themRNA ofHMGA2, a gene
highly expressed during development and in tumor tissue,
can sequester let-7 away from its cellular targets [129].
This sequestration promotes the progression of NSCLC.
It will be important to examine the expression profile of
these ceRNAs in cancer samples, given that dysregulation
of these miRNA sponges can produce striking phenotypes.
Furthermore, this complex communication between pseu-
dogenes, miRNAs, and mRNA transcripts affects the valida-
tion of putative miRNA targets, given that certain cells may
have high levels of a particular pseudogene acting as a
sponge or target decoy. New databases (i.e. ceRDB) are
emerging to identify ceRNA interactions on a genome-wide
scale [130,131]. Additionally, elucidating ceRNA biology in
the normal cells from which the cancer arises will be crucialsince Denzler et al. [132] recently found that modulating the
abundance of one canonical miR-122 target (AldoA) in
normal hepatocytes did not significantly affect other miR-
122 target genes. Furthermore, global miR-122 target site
abundance was not sufficiently different in a metabolic liver
disease model to alter miR-122-mediated gene repression,
arguing that ceRNAs are not involved in this biology. Howev-
er, if ceRNA levels can approach miRNA target site abun-
dance, as may be the case in the PTEN story described
above, then ceRNAs may indeed regulate miRNA activity.
Therefore, more effort will be required to determine the
extent of the ceRNA network in cancer and the implications
for the pathophysiology of this disease.
Single Nucleotide Polymorphisms/Mutations
SNPs are naturally occurring variations in the DNA sequence;
they have been studied in great detail and found to predict
disease associations for particular populations. A number
of studies have identified how miRNA regulation of mRNA
transcripts can be disrupted by the presence of certain
SNPs within those respective targets.
Specifically, Saunders et al. [133] identified polymor-
phisms that occur predominantly in the DNA sequence flank-
ing pre-miRNAs but less so within the miRNA sequences
themselves. It appears that SNPs distribute near putative
miRNA target sites, though this cannot be completely veri-
fied given that not all miRNA targets have been experimen-
tally validated. Specifically, a bioinformatics approach was
used to scan putative miRNA target sites within the 30UTR
of respective mRNA genes, and this data set was overlaid
with SNP array data [133–135]. A theme that emerged was
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are under positive selection pressure in order to avoid
miRNA-mediated downregulation of gene expression. How-
ever, this can lead to the perpetuation of SNPs that may
contribute to disease phenotypes. In NSCLC, KRAS is an
oncogene with identified SNPs that associate with risk of
developing the disease. Specifically, an SNP in a putative
let-7-binding site in the KRAS mRNA not only was associ-
ated with a 2.3-fold increased risk for developing NSCLC,
but also led to disruption of let-7 binding to KRAS [136].
Other examples where SNPs affect miRNA-target interac-
tions include miR-221 and the receptor tyrosine kinase KIT
in papillary thyroid carcinoma and melanoma [137,138],
and miR-189 and the transmembrane protein SLITRK1 in
Tourette’s syndrome [139].
SNPs found in pre-miRNAs themselves can disrupt the
processing of these miRNAs since proper nucleotide base-
pairing is crucial for proper miRNA biogenesis [140]. An
example of this is a germline mutation 7 nt downstream of
mir-16 in chronic lymphocytic leukemia that abolishes the
expression of both miR-15a and miR-16-1 [141]. Further-
more, an SNP in mir-125a can block pri-miR-125a process-
ing, reducing miRNA-mediated repression of LIN28 target
RNA [142]. Sequence variations can also be found in the
transcripts encoding miRNA biogenesis proteins such as
DICER [143], and these SNPs can associate with diseases
including cancer. While it is exciting that a single nucleotide
variation in DNA can affect miRNA biogenesis and activity,
further effort is required to understand the functionality of
miRNA–SNP interactions, and whether these interactions
can promote tumorigenic events.
Conclusions
As highlighted in this review, the pervasive dysregulation of
miRNA-mediated gene regulatory networks are evident in
many cancer models. MiRNAs function as master regulators
and signal modulators by fine-tuning gene expression, a pro-
cess that, when disrupted, allows for a permissive tumori-
genic state. While it has been known for some time that
miRNAs can regulate mRNA transcripts, and that disruption
of this process can result in tumorigenesis, what was less
well understood was how miRNAs were themselves regu-
lated. Transcription of miRNA genes primarily depends
upon RNA polymerase II, and so it should be no surprise
that miRNAs are under similar regulatory constraints as
protein-coding transcripts (i.e. transcriptional activation/
inhibition and DNA methylation). However, the surprising
finding in the past few years has been the extent to which
miRNAs are regulated at the post-transcriptional level, either
by RBPs, RNA editing, or modulation of miRNA decay, and
how tumor cells can subvert these regulatory processes.
Furthermore, it appears that there is a complex ceRNA
communication network and it will be interesting to see
how this RNA network, in all its complexity, can contribute
to specific cellular phenotypes such as transformation,
epithelial-to-mesenchymal transition, and generation of
cancer stem cells. Given this complexity, the tumorigenic
environment may rely more on the disruption of RNA-medi-
ated gene regulatory networks than was previously appreci-
ated. Indeed, it is known that miRNA expression profiles
can classify tumor subtypes more effectively than mRNA
profiles [11], suggesting a substantial role for miRNAs in
the regulation of malignant biological processes by regu-
lating mRNA transcripts that result in tumor progression.Finally, expression of miRNAs can convert a noisy tran-
scriptional network into a concerted or dedicated bimodal
switch system that can direct cell fates. Furthermore, the
identification of miRNAs that can promote cancer stem cell
formation, or protect these cells from insults such as chemo-
therapeutic agents, will be an important discovery. Those
miRNAs could then be targeted by antisense-based thera-
pies in the clinic to sensitize the cancer stem cell population
to current clinical regimens for the particular tumor type.
Overall, there has been a recent explosion of knowledge in
miRNA biology and, as more discoveries are made in the
non-coding RNA field, hopefully some of these findings can
soon be translated into promising clinical advances.
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